Garuda - Garba Rujukan Digital

p-Index From 2021 - 2026

4.761

P-Index

This Author published in this journals

All Journal Farmasains : Jurnal Farmasi dan Ilmu Kesehatan Jurnal Kedokteran Brawijaya Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Media Farmasi : Jurnal Ilmu Farmasi (Journal Of Pharmaceutical Science) Jurnal Kesehatan Jurnal Farmasi Klinik Indonesia Pharmacon MPI (Media Pharmaceutica Indonesiana) Pharmascience JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Pharmasipha PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) JFIOnline Pharmaceutical Journal of Indonesia JFM (Jurnal Farmasi Malahayati) JURNAL FARMASIMED (JFM) Majalah Farmasetika Jurnal Ilmiah Farmasi Farmasyifa Budapest International Research in Exact Sciences (BirEx Journal) Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Jurnal Farmasi dan Sains Indonesia (JFSI) Indonesian Journal of Pharmaceutical Education Jurnal Riset Farmasi Journal of Global Pharma Technology Journal of Tropical Pharmacy and Chemistry Jurnal Sains dan Kesehatan Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Folia Medica Indonesiana

Didik Hasmono

Department Of Clinical Pharmacy, Faculty Of Pharmacy, Universitas Airlangga

Author-ID : 278212

Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Education Environmental Science Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Transportation Other

Published : 74 Documents Claim Missing Document

Claim Missing Document

Articles

1 2 3 4 5

Studi Penggunaan Flukonazol pada Pasien HIV/AIDS dengan Infeksi Oportunistik Jamur: Penelitian di RSUD Dr. Saiful Anwar Irsan Fahmi Almuhtarihan; Didik Hasmono; Hidajah Rachmawati; Agus Sunarko
MPI (Media Pharmaceutica Indonesiana) Vol. 2 No. 4 (2019): DECEMBER
Publisher : Fakultas Farmasi, Universitas Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24123/mpi.v2i4.1882

AIDS is characterized by a transition of opportunistic infections. The most common opportunistic infection is candidiasis with prevalence among HIV patients between 80% to 95%. Fluconazole is the main treatment for candidiasis, but combination with nystatin is often done. This study aims to determine the pattern of fluconazole dosages, dosage forms, and combinations given to HIV/AIDS patient with opportunistic fungal infection. This observational retrospective study was conducted on HIV/AIDS patients who were hospitalized with opportunistic fungal infections in the period of January 1st, 2015 to December 31st, 2015 who received fluconazole. Thirty-five patients were included in this study. Fluconazole monotherapy was used by 21 patients (43%), while combination therapy with nystatin was used by 28 patients (57%). Fluconazole monotherapy was generally preceded by the loading dose (1×400 mg) IV drip followed by maintenance doses (1x200 mg) IV drip in 6 patients (24%), whereas the combination of fluconazole and nystatin was generally used as fluconazole (1×200 mg) IV drip and nystatin (3×300,000 IU) PO in 7 patients (14%). Oral fluconazole was mostly (86%) given less than five days, whereas fluconazole IV drip was mostly (43%) given for 6-10 days. The patterns of fluconazole dosages, dosage forms, and combinations given to HIV/AIDS patient with opportunistic fungal infection was appropriate.

Profil Terapi dan Efek Samping Anti Tuberkulosis pada Pasien AIDS Rawat Inap Claudia Tiffany; Didik Hasmono; Agus Sunarko
MPI (Media Pharmaceutica Indonesiana) Vol. 2 No. 4 (2019): DECEMBER
Publisher : Fakultas Farmasi, Universitas Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24123/mpi.v2i4.1922

AIDS is a global problem, including in Indonesia. AIDS patients are easy to get pulmonary tuberculosis. These patients will receive polypharmacy which require special attention to ensure patient safety. The objective of this study is to examine the usage patterns of anti-tuberculosis therapy in AIDS patients related to types, route, dose, and see whether there are any side effects during anti-tuberculosis use. This was observational and retrospective study using patient medical record, conducted at dr. Saiful Anwar hospital, Malang in the period of April-Mei 2016. Based on medical record of 36 AIDS patients with pulmonary TB, 22 patients (61%) were in the intensive phase of treatment anti-tuberculosis cate–gory I, 8 patients (22%) in the treatment of the intensive phase of category II, 2 patients (6%) in the continuation phase category I, 1 patient (3%) was in the intensive phase of category I then get a special conditions regimen of anti-tuberculosis therapy, 1 patient (3%) was in the intensive phase category II but underwent a change to the intensive phase of MDR-TB, and other 1 patient (3%) was get the intensive phase of special conditions. Drug related problems that identified were rash (6%), Steven Johnson syndrome (3%), drug induced hepatitis due to anti-tuberculosis (22%), and jaundice without other cause (3%).

Kajian Literatur: Tinjauan Remdesivir sebagai Pilihan Terapi pada COVID–19 Wien Maryati Awdisma; Ulfa Syafli Nosa; Didik Hasmono; Nurmainah Nurmainah
Jurnal Pharmascience Vol 8, No 2 (2021): Jurnal Pharmascience
Publisher : Program Studi Farmasi FMIPA Universitas Lambung Mangkurat

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20527/jps.v8i2.11650

Infeksi virus corona baru, pertama kali terdeteksi pada akhir Desember 2019, dengan jumlah kasus terkonfirmasi lebih dari 33 juta kasus dan lebih dari 900.000 kematian dilaporkan. Terdefinisi sebagai pandemi, dan belum ada “obat khusus” yang dianggap dapat mengatasinya. Salah satu pendekatan terapeutik yang sedang dievaluasi dalam berbagai uji klinis adalah saat ini adalah remdesivir,telah disetujui oleh Badan Pengawas Obat dan Makanan (BPOM sebagai obat Emergency Use Authorization (EUA) sebagai opsi penggunaan darurat Tujuan penulisan ini untuk memberikan gambaran tentang penemuan remdesivir, mekanisme aksi, dan penelitian terkini yang mengeksplorasi efektivitas klinisnya. Metode penelitian dilakukan dengan pencarian sumber data PubMed, Google Scholar, Science Direct dan Cochrane hingga November 2020 dengan kata kombinasi kata kunci Convalescent Plasma”; “SARS-CoV-2”, Virus Corona dan dibatasi pada jurnal berbahasa Inggris. yang mengulas penemuan remdesivir, mekanisme kerja, farmakokinetik, farmakodinamik, dan efikasi uji klinis remdesivir dalam pengobatan pasien COVID-19. Kesimpulan dari penelitian ini bahwa remdesivir memiliki efek klinis yang baik setelah 10 hari pengobatan pada pasien COVID-19.Kata Kunci: COVID-19, EUA, Remdesivir, SARS-CoV-2 The new coronavirus infection identified at the end of December 2019 and is receiving a lot of attention around the world. Globally, the number of confirmed cases has increased to more than 33 million cases and more than 900,000 deaths have been reported. This condition is defined as a pandemic situation, and so far no "special drug" is believed to be able to overcome it. One therapeutic approach currently being evaluated in various clinical studies is remdesivir. This drug is approved by the Food and Drug Administration (BPOM) as Emergency Medicine (EUA). This emergency option for remdesivir is considered a promising option for treating patients with COVID19. The purpose of this paper is to provide an overview of recent studies investigating the discovery of remdesivir, its mechanism of action, and its clinical efficacy. The survey method was conducted by searching the data sources of PubMed, Google Scholar, Science Direct, and Cochrane until November 2020. Researchers limit literary studies to English journals. The results of 1000 articles searched that met the selection criteria were 10 articles examining the results of remdesivir, its mechanism of action, pharmacokinetics, pharmacodynamics, and the efficacy of clinical remdesivir in the treatment of patients with COVID 19. The conclusion of this study is that remdesivir has a good clinical effect 10 days after treatment of patients with COVID19.

Injektabel Komposit Hydroksiapatit-Gelatin sebagai Sistem Penghantaran Alendronat Aniek Setiya Budiatin; Junaidi Khotib; Didik Hasmono; Samirah Samirah
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 3 No. 1 (2016): Jurnal Farmasi dan Ilmu Kefarmasian Indonesia
Publisher : Universitas Airlangga

Background: Bisphosphonates, such as alendronate (ALE), have been known to be effective in the treatment of bone cancer and osteoporosis. However, it has been reported that the systemic administration of ALE causes a considerable side effect. Thus, the formulation injectable bone substitute (IBS) for local administration of ALE, which functions as drug delivery system (DDS) as well as filling agent in osteoporosis-induced bone fracture, is needed. Objective: To establish the biodegradable and biocompatible formulation for ALE in injectable form which supports the drug delivery system and acts as filling agent in bone fracture. Methods: Hydroxyapatite (HA) was added to the mixture of gelatin and hydroxypropyl methyl cellulose (GEL-HPMC). ALE was added to the mixture and semisolid form was prepared for granulation. The dried granule, as injectable matrix, was grinded and mixed with appropriate amount of Na2HPO4. Results: Porosity of injectable form was higher than those of granule form. Injectable semisolid form was produced by adding 0.8 mL Na2HPO4 on each gram of granule with 10-12 min setting time. MTT assay showed that matrix was biocompatible showed by more than 100% viability. In vitro dissolution study showed that ALE was slowly released in more than 20 days. Conclusions: The formula of IBS using HA-GEL-HPMC may act as an effective drug delivery system for local administration of ALE in bone fracture.

Drug Utilization Study of Antibiotics in Bacterial Meningitis (A Retrospective Study in Dr. Soetomo General Hospital, Surabaya, Indonesia) Mareta Rindang Andarsari; Didik Hasmono; Samirah Samirah; Suharjono Suharjono; Dea Ayu Nabilah; Paulus Sugianto
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 4 No. 2 (2017): Jurnal Farmasi dan Ilmu Kefarmasian Indonesia
Publisher : Universitas Airlangga

Background: Meningitis defined as an inflammation of the meninges, a membrane that surrounds the brain. The inflammation is a result from bacterial infection. Central nervous system infection is a medical emergency because of the progressivity and potentially life-threatening. Antibiotics usage become crucial to reduce morbidity and mortality. Objective: This study was aimed to assess the use of antibiotics, prescribed for patients with bacterial meningitis in Neurology Department of Dr. Soetomo General Hospital Surabaya from January 2010 until June 2015. Methods: Retrospective study using medical record of inpatients obtained from January 1st 2010 until June 30th 2015. The inclusion criteria were inpatients with bacterial meningitis (diagnosed by physician using CT scan data, lumbal puncture and clinical signs and symptoms) and prescribed with antibiotics. Patients with antibiotics therapy less than 3 days and infection other than bacterials were excluded. Results: From 85 patients, male to female ratio was 1.66. Meningitis appear to be mostly occured in productive age, 39 (45.88%) in 15 - 29 years old and 40 (47.06%) in 30 - 60 years old. Number of antibiotics prescribed were 130 prescriptions, as single and combination therapy. The most prescribed antibiotic was cephalosporins (97 prescriptions), dominated by 2 g twice daily ceftriaxone with 86 (66.15%) from overall prescriptions. Followed by metronidazole and fluoroquinolons,11 (8.46%) and 8 (6.15%) respectively. In addition, there were 26 prescriptions of combination therapy, mostly ceftriaxone and metronidazole. Conclusion: Bacterial meningitis are mostly treated using ceftriaxone which is an appropriate drug of choice.

Practical Analysis Antibiotics Use for Covid 19 Patients Puri Safitri Hanum; Ni Made Eravikania Putri Darmawan; Didik Hasmono
Budapest International Research in Exact Sciences (BirEx) Journal Vol 3, No 4 (2021): Budapest International Research in Exact Sciences, October
Publisher : Budapest International Research and Critics University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33258/birex.v3i4.2636

To evaluate the use of antibiotics and their effectiveness in COVID-19 patients including PCR, body temperature, SaO2, chest X-ray, respiratory rate, leukocytes, CRP, and LOS of COVID-19 patients at Bhayangkara HS Samsoeri Hospital Mertojoso Surabaya. This study is an observational study with a retrospective method in the period June 2020 to February 2021. Data were collected from Medical Records of COVID-19 patients who achieved antibiotic therapy, with standard therapy: antiviral (mild to moderate: Favipiravir-Ritonavir and severe: Remdesivir), antibiotics, vitamins, anticoagulants, corticosteroids, symptomatic and concomitant therapy. The study showed that 37% (25 patients) were female and 67% (41 patients) were male with the highest age range between 30-39 years. Most of the patients were hospitalized for 10-14 days and the longest hospitalization period was 40-44 days. In this study patients with mild cases were the most cases with a total of 36 patients (54%). The results of the analysis based on the 2020 Third Edition of the 2020 COVID-19 Handling Guidelines, the Bhayangkara Hospital Antibiogram data, clinical conditions and laboratory tests occurred in 66 patients (100%). Rational use of antibiotics in accordance with the COVID-19 Management Guidelines 3rd Edition and data from Bhayangkara Hospital antibiogram of 100% and antibiotics can help the healing process of COVID-19 patients proven by negative PCR results (91%), increased body temperature (100%), SaO2 (100%), chest x-ray (45%), respiratory rate (92%), leukocytes (77%), CRP (41%), and LOS.

STUDI PENGGUNAAN OBAT NEUROPROTEKTAN PADA PASIEN STROKE ISKEMIK (Penelitian Di Rumah Sakit Umum Dr. Saiful Anwar Malang) Dini Setiya Praja; Didik Hasmono; Nailis Syifa
PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) Jurnal Pharmacy, Vol. 10 No. 02 Desember 2013
Publisher : Pharmacy Faculty, Universitas Muhammadiyah Purwokerto

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30595/pji.v10i2.796

ABSTRAK Stroke adalah sebuah penyakit pada sistem saraf yang disebabkan penyumbatan atau terjadinya luka pada pembuluh darah di otak. Stroke merupakan penyebab kelumpuhan nomor satu di dunia, pembunuh nomor dua di dunia dan merupakan peringkat ketiga penyebab kematian di Amerika Serikat. Stroke iskemik adalah stroke yang paling sering terjadi dengan angka kejadian 88%. Tujuan pengobatan stroke akut adalah menurukan terjadinya kerusakan saraf lebih lanjut dan menurunkan kematian dan kelumpuhan jangka panjang. Neuroprotectan adalah salah satu terapi yang dapat menurunkan kerusakan sel yang mengakibatkan gangguan pembuluh darah untuk mensuplai oksigen. Penelitian bertujuan untuk menentukan pola penggunaan neuroprotectan pada pasien dengan stroke iskemik serta memeriksa hubungan terapi neuroprotectan terkait dosis, rute pemberian, frekuensi pemberian, lama dan waktu pemberian yang dikaitkan dengan data klinik di rumah sakit Dr. Saiful Anwar Malang. Penelitian ini menggunakan pengamatan retrospektif dengan consecutive sampling method pada pasien stroke iskemik dari bulan Oktober 2012 sampai Desember 2012. Pada penelitian ini menunjukkan bahwa 95 pasien (93,14%) menerima citicoline, 2 pasien (4,90%) menerima piracetam, dan 5 pasien (4,90%) menerima kombinasi citicoline dan piracetam. Neuroprotectan yang digunakan secara i.v. dan oral dengan (2x1g)/i.v. citicoline kemudian (2x1g)/p.o sebanyak 27 pasien (26,47%). Penggunaan dosis neuroprotectan, rute pemberian, interval pemberian, dan lama pemberian yang diberikan pada pasien stroke iksemik di rumah sakit Dr. Saiful Anwar sudah sesuai berdasarkan beberapa guidelines yang ada. Kata kunci: neuroprotektan, rumah sakit, stroke iskemik. ABSTRACT Stroke is a neurological disease caused by a blockage or rupture of blood vessels in the brain. Stroke is the number one cause of disability in the world, the second leading killer worldwide and the third leading cause of death in the United States. Ischemic stroke is the most common type of stroke that occurs 88%. The goal of acute stroke treatment are to reduce the ongoing neurologic injury and decrease mortality and long-term disability. Neuroprotectan is one of therapy that intended to reduce the occurrence of cell damage due to impaired blood flow to supply oxygen.The study aims to determine patterns of neuroprotectan utilization in patient with ischemic stroke and to examine the relationship neuroprotectan therapy related to the dose, route of administration, frequency of administration, duration and timing of administration associated with clinical data at the Hospital of Dr. Saiful Anwar Malang. The study is a retrospective observational with consecutive sampling method in ischemic stroke patients from october to december 2012. This study showed there were 95 patients (93.14%) received citicoline, 2 patients (4.90%) received piracetam, and 5 patients (4.90%) received combination of citicoline-piracetam. Neuroprotectan used by i.v and oral administration dominated with (2x1g)/iv citicoline then (2x1g)/p.o as 27 patients (26,47%). The use of neuroprotectan dose, route of administration, interval of administration, and duration of administration that given in ischemic stroke patients in inpatient Dr. Saiful Anwar was appropriate according to some existing guidelines. Key words: neuroprotectan, inpatients, ischemic stroke.

Studi Penggunaan Obat Anti Tuberkulosis (OAT) Tahap Lanjutan pada Pasien Baru BTA Positif Tista Ayu Fortuna; Hidajah Rachmawati; Didik Hasmono; Hidayah Karuniawati
Pharmacon: Jurnal Farmasi Indonesia Vol 19, No 1 (2022)
Publisher : Universitas Muhammadiyah Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23917/pharmacon.v19i1.17907

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Tuberculosis will cause pain and death if not treated properly. OAT (Antituberculosis Drugs) is a treatment for tuberculosis patients. OAT has different dosage regimens and types of drugs. Treatment of TB patients consists of two phases (intensive and continuation phases). The continuation phase was at to kill dormant bacteria to prevent recurrence in patients. The purpose of this study was to determine and evaluate the pattern of using OAT in patients newly diagnosed rwith smear-positive at the continuation phase. This study is an observational descriptive study with results showing that the pattern of using OAT-KDT in patients was 89% and OAT-Separated was 11%. The pattern of using the OAT-KDT dose was 1x3 2KDT tablets. Another combination of antibiotics given to the patient is cotrimoxazole at a dose of 1x960mg. The side effect of OAT is an increase in serum transaminase and nausea each with a percentage of 23%. Based on the research, it can be concluded that the pattern of using OAT in Tuberculosis patients has followed the guidelines for the management of Tuberculosis treatment.

STUDY OF EFFECTIVENESS AND SIDE EFFECTS OF FAVIPIRAVIR THERAPY ON MILD AND MODERATE COVID-19 PATIENTS Didik Hasmono; Alfa Frista Arta; Ismawati; Ruddy Hartono; Mohammad Subhan
Jurnal Kesehatan Vol 15 No 2 (2022): JURNAL KESEHATAN
Publisher : Universitas Islam Negeri Alauddin Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24252/kesehatan.v15i2.29380

Introduction: Corona Virus Disease-2019 (COVID-19) is divided into five degrees that are asymptomatic, mild, moderate, severe and critical. Recently, Favipiravir known as off-label antivirals for COVID-19 that inhibits RNA-dependent RNA polymerase (RdRp) and is administered orally 2x1600 mg as loading dose and 2x600 mg as a maintenance dose. Methods: This observational retrospective study aims to determine effectiveness (PCR/Rapid Ag, temperature, respiratory rate, oxygen saturation, and chest X-ray) and side effects (digestive, uric acid, liver, blood, glucose, and lipids profile) of Favipiravir in mild and moderate COVID-19; which inclusion criteria were Favipiravir (5-10 days); a group of antibacterials: Azithromycin (therapy A), Levofloxacin (therapy B), and combination (therapy C); vitamins, minerals, symptomatic and comorbid therapy; and Fondaparinux used in moderate degree then described quantitatively. Results: This study obtained 47 HMR dominated by males (55%), aged 19-30 years (36%), cough symptoms (72,3%), and no comorbid status (70.2%). Favipiravir (6-7 days) is effective for mild and moderate degree in all effectiveness parameters with average length in mild degree was 6-12 days and moderate degree was 8-13 days. Possible interaction with Paracetamol was found. Most side effects were diarrhea and no significant side effects were found on liver profile (AST and ALT), glucose profile, and blood profile (leukocytes and erythrocytes). Conclusions: This result suggests that increasing collaboration of pharmacists with other healthcare in monitoring the use of Favipiravir related to interactions, uric acid, and lipid profiles, also effects in patients under 18 years, men, and elderly is important.

Isoprinosine along with Favipiravir or Oseltamivir in Patients with Moderate Covid-19 at RSD Dr. Soebandi Jember Chrysnanda Maryska; Didik Hasmono; Sofiati Diah Baisuni; Ayunda Nur Hidayatiningsih; Arina Dery Puspitasari; Retna Dwi Puspitarini; Budi Suprapti
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 9 No. 3 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v9i32022.209-219

Background: Isoprinosine is an immunomodulator that is now being used to treat Covid-19 patients. Objectives: To evaluate Isoprinosine with Favipiravir or Oseltamivir in moderate Covid-19. Methods: In a retrospective observational analysis, in-hospital moderate Covid-19 patients treated between June 2020 and June 2021 were included. Results: Inclusion criteria for 364 patients were met, with 135 receiving Favipiravir-Isoprinosine (Group 1) and 229 receiving Oseltamivir-Isoprinosine (Group 2). In group 1, the majority of patients (58.50%) were female (35.60%), had no comorbidities (71.60%), were discharged with a positive PCR (74.80%), did not require a breathing apparatus (99.26%), had leukocyte levels between 4,5-11,0 (82.22%), lymphocyte levels between 25-33 (34.07%), and were discharged with no ground-glass opacity (34.07%) (54.10%), LOS was 9-13 days (50.37%), while the mortality rate was 0.70%. In group 2, the majority of patients were male (54.10%), with the highest age range being 42-56 years (35.80%), without comorbidities (69.0%), discharged with a positive PCR (72.50 %), and without the need for a breathing apparatus (99.13%), with leukocyte levels ranging from 4.5 – 11.0 (81.22 %), with lymphocyte levels ranging from 25.0 – 33.0 (26.20 %), and were discharged with no ground-glass opacity (49.34 %), LOS was 9 - 13 days (34.06 %), and the mortality rate was 0.87%.Conclusion: In this trial, it was determined that combining isoprinosine with antivirals favipiravir or Oseltamivir could produce significant clinical improvement.

Co-Authors Adinugraha Amarullah Aghnia Fuadatul Inayah Agriawan Sudirman Agriawan Sudirman Agus Sunarko Agus Sunarko Alfa Frista Arta Alfin Giovani Amanda, Anita Tria Amarullah, Adinugraha Andilusia, Sindy Ardianty, Nonie Arina Dery Puspitasari Aryani, Dhita Aryani, Dhita Evi Astutik, Widi Atika Putri Kusumaningtyas Atmajani, Wanudya Awdisma, Wien Maryati Ayumuyas, Nur Palestin Ayumuyas, Nur Palestin Ayunda Nur Hidayatiningsih Badriyah, Rani Nur Bambang Sidharta Binti Muzayyanah Budi Suprapti Budiatin, Aniek Setiya Bura, Ursula Dua Klowe Chrysnanda Maryska Claudia Tiffany Dea Ayu Nabilah Dinda Monika Nusantara Ratri Dini Setiya Praja Dini Setiya Praja, Dini Setiya Donsu, Yosefien Christania Elisabeth Kasih Fadlilah, Umul Firandi, Adelia Ganesha T Trengginas Giovani, Alfin Hadiyanti, Nur Hanum, Putri Safitri Hariyati, Fera Hariyati, Fera Hartono, Ruddy Hasbi As-Shiddiq Hendra Yadi Heni Pujiastuti Hidajah Rachmawati Hidajah Rachmawati Hidayah Karuniawati Hidayah, Ana Nurlaili IGD Ugrasena Ilfi Hanna, Az Zahra Insyirah Idris, Anissah Irianto, Jimmy Setiawan Irsan Fahmi Almuhtarihan Irsan Fahmi Almuhtarihan Ismawati Isparnadi, Erwien Issaura, Issaura Jenggo Suwarko Joko Semedi Junaidi Khotib Khairil Armal Kuntaman Kuntaman Kusumaningrum , Yunita Dyah Kusumaningtyas, Atika Putri Lilik Yusetyani Lilik Yusetyani Ma'rifah, Nurul Machin, Abdulloh Mahardian Rahmadi Mareta Rindang Andarsari Maria Angelia Yoshida Meiliana, Made Laksmi Meo, Maria Lettisia Mia Melinda Mohammad Saiful Islam Mohammad Saiful Islam, Mohammad Saiful Mohammad Subhan Mohammad Subhan Mohammad Subhan Mohammad Subkhan Muhammad Nashrullah Muktamiroh Muktamiroh Muzayyanah, Binti Nadriatul Utami Nadriatul Utami Nailis Syifa Ni Made Eravikania Putri Darmawan Nun Zairina, Nun Nur Hadiyanti Nuraida Wisudani Nurfausiah, Nurfausiah Nurmainah Nurmainah Nurul Ma'rifah Paulus Sugianto Pharmasinta Putri Hapsari Pramadani, Yana Puri Safitri Hanum Puspitasari, Diny Putri Nurhidayah, Eka Ramdani, Dewi Retna Dwi Puspitarini Rino Wahyudi, Rino Risa Septinia Rizki Lisya Nugraha Roni Subagyo RR. Ella Evrita Hestiandari Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruhaya Fitrina, Ruhaya Samirah Samirah Sandra J. Parambang Sandra, Pipit Semedi, Joko Sendi Lia Yunita Setiawan, Landia Siti Surdijati Siti Surdijati, Siti Sofiati Diah Baisuni Subagyo, Roni Suharjono Suharjono, Suharjono Sumarno Sumarno Syifa', Nailis Syifa, Nailis' Tanasy, Marledy Taufiqur Rahman, Taufiqur Thayyib, Muqoddar Tista Ayu Fortuna Trengginas, Ganesha T Ugrasena, IGD Ulfa Syafli Nosa Usman Hadi Utami, Nadriatul Wardhani, Firdha Aprillia Wardhani, Hety Setya Widi Astutik Widi Astutik Wien Maryati Awdisma Wiranata, I Made Wisudani, Nuraida Worotikan, Natania Imanuella Yosefien Christania Donsu Yudi Agung Wibisono Yudistira Nurrizky Grahitaning Putra Rohmaana Yulistiani Yulistiani Yulistiani Yulistiani, Yulistiani Yulistiani, . Yuni, Santi Eka Yuni, Santi Eka

Title

Found 74 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 74 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 74 Documents
Search